Background. Although an age cutoff of 45 years has often been adopted to stratify cancer risk in papillary thyroid carcinoma (PTC), both cancer-specific survival (CSS) and disease-specific survival (DFS) continue to worsen beyond this cutoff. This study aimed to determine whether advanced age (i.e., [60 years) at diagnosis was an independent predictor of CSS and DFS in older (C45 years) patients. Methods. This study analyzed 407 PTC patients with a minimal follow-up period of 7 years. Standard protocol was followed. Both CSS and DFS were estimated using the Kaplan-Meier method and compared with the log-rank test. Variables shown to be significant by the log-rank test were entered into the Cox regression analysis. Conclusions. Advanced age was an independent predictor of CSS, and cancer-related death risk showed a continuing increase beyond the age of 60 years. However, advanced age was not an independent predictor of DFS. Therefore, having another age cutoff appears justifiable for stratifying risk of cancer-related death but less justifiable for disease recurrence. Tumor size as well as central and lateral nodal metastases independently predicted CSS and DFS.
p = 0.017), lateral nodal metastases (HR 5.247; 95 % CI 2.987-9.216; p \ 0.001), and distant metastases (HR 4.297; 95 % CI 1.726-2.506; p = 0.002) were independent predictors. For DFS, only tumor size greater than 4 cm (HR 1.733; 95 % CI 1.030-3.058; p = 0.049), central nodal metastases (HR 2.362; 95 % CI 1.010-5.523; p = 0.047), and lateral nodal metastases (HR 4.383; 95 % CI 2.388-8.042; p \ 0.001) were independent predictors. Conclusions. Advanced age was an independent predictor of CSS, and cancer-related death risk showed a continuing increase beyond the age of 60 years. However, advanced age was not an independent predictor of DFS. Therefore, having another age cutoff appears justifiable for stratifying risk of cancer-related death but less justifiable for disease recurrence. Tumor size as well as central and lateral nodal metastases independently predicted CSS and DFS.
Papillary thyroid carcinoma (PTC) is the most common type of thyroid carcinoma, and its incidence has doubled in the past two decades. 1 Although PTC generally is associated with an excellent outcome, its prognosis depends on the presence of certain clinicopathologic characteristics. 2 Age at diagnosis has long been recognized as one of the most important prognostic factors in PTC. 2, 3 Given that patients younger than 45 years have a significantly better prognosis than those 45 years of age or older, many risk stratification systems, including the more popular 7th edition of the International Union of Against Cancer (UICC) TNM (tumor, node, and metastasis) staging system, use an age cutoff of 45 years to stratify risk. 3 Although this strategy might be convenient, it assumes that all patients older than 45 years have a fairly uniform tumor risk regardless whether they are significantly older or closer to Brian Hung-Hin Lang-ORCID: 0000-0002-9362-0086.
Electronic supplementary material The online version of this article (doi:10.1245/s10434-014-4055-1) contains supplementary material, which is available to authorized users. the age cutoff. However, it is becoming increasingly clear that the risk of both cancer-related death and disease recurrence progressively increases even after the age of 45 years. [4] [5] [6] [7] [8] [9] In fact, some groups have proposed that perhaps another age cutoff of 60 years should be considered in the stratification of tumor risk and individual treatment for older (C45 years) patients. [4] [5] [6] However, to our knowledge, their studies did not account for other significant prognostic factors. Furthermore, most of their patients had microcarcinoma, so less than half of their patients underwent total or near-total thyroidectomy and received radioactive iodine (RAI) afterward.
Given these issues, our study aimed to determine whether advanced age at diagnosis (i.e., [60 years) remained an independent predictor of cancer-specific survival (CSS) and disease-free survival (DFS) in older patients. This investigation was performed by analyzing a large patient cohort that had experienced clinically significant PTC requiring total or near-total thyroidectomy and RAI ablation afterward and had been followed up for a median of 15 years.
PATIENTS AND METHODS
From 1970 to 2006, 988 consecutive patients with histologically proven PTC underwent total or near-total thyroidectomy at our institution. Of these patients, 33 (3.3 %) with incomplete follow-up data, 107 patients (10.8 %) with microcarcinoma (\1 cm) and 441 patients (44.6 %) younger than 45 years were excluded from the study. Therefore, 407 patients (41.2 %) with a minimal follow-up period of 7 years were eligible for analysis.
To ensure an accurate and updated follow-up status of all the patients, a careful manual search of all patients' status in the territory-wide Clinical Management System (CMS) was performed. The CMS, a computerized database linking all public hospitals, provides inpatient medical records corresponding to more than 90 % of inpatient bed days in the territory. The date of the latest follow-up assessment or death and the cause of death were recorded from the CMS. All causes of death were further confirmed by careful examination of the medical record, autopsy report, or death certificate. All relevant clinical, pathologic, and perioperative data were collected prospectively after 1994, and follow-up data were regularly updated in a computerized database.
Management of PTC
Details of surgical treatment, RAI ablation criteria, postoperative care, and follow-up protocol had been described previously. 2 Preoperative lymphatic mapping by neck ultrasound (USG) was not performed routinely until later in the study. Total or near-total thyroidectomy was preferred for all patients with a preoperative diagnosis of PTC. Simultaneous therapeutic central (level 6) and lateral (levels 2-5) selective neck dissection was performed for clinically proven cervical nodal metastasis. Prophylactic level 6 neck dissection was not routinely performed. At 2 months after initial surgery, a standard ablative RAI dose of 3 giga-Becquerels (GBq) or 80 millicuries (mCi) was administered after LT4 withdrawal or with recombinant thyroid-stimulating hormone (TSH). Immediately afterward, TSH-suppressive LT4 treatment was started, followed by the posttherapy scan 4-7 days later. The subsequent therapy for distant metastases usually comprised 5.5 GBq (or 150 mCi) RAI administered periodically every 6 months until the scan showed no more uptake or the disease progressed despite treatment. The decision for RAI ablation was based on the presence of one or more risk factors such as tumor larger than 1.5 cm, lymph node metastasis, age beyond 45 years, extrathyroidal extension, possible postoperative neck residual disease, and distant metastasis. External beam radiotherapy (EBRT) to the neck was given to patients with extensive extrathyroidal tumor extension, incomplete resection, or extracapsular nodal metastasis. In some cases of incomplete resection, EBRT was given before RAI.
Follow-Up Protocol
All the patients were followed up postoperatively within 4 weeks in our specialized clinic. A follow-up visit was conducted every 3-6 months during the first 5 years and annually thereafter. Clinical examination and thyroglobulin (Tg) were performed at each visit. Disease recurrence generally was determined by a combination of basal Tg trend, USG, and computed tomography (CT)/magnetic resonance imaging (MRI) or positron emission tomography with [F 18 ]-labeled fluorodeoxyglucose (PET-FDG) scan and confirmed by fine-needle aspiration cytology (FNAC) or histology if possible, whereas locoregional recurrence (LRR) was defined as an identifiable neck lesion shown by USG and confirmed on FNAC or histology. 10 The exact location of LRR and distant recurrence were recorded. To simplify the analysis for DFS and disease recurrence, those presenting with distant metastases were excluded from the analysis.
Statistical Analysis
Estimates of CSS and DFS were performed using the Kaplan-Meier method and compared with the log-rank test. Variables that were significant in the univariate analysis (by log-rank test) were entered into the multivariate analysis using Cox-regression analysis. All statistical analyses were performed using SPSS version 18.0 (SPSS, Inc., Chicago, IL, USA).
RESULTS
The cohort included mostly women (73.2 %) and ethnic Chinese (92.4 %) with a mean age of 60.0 ± 10.9 years and a mean tumor size of 2.3 ± 0.9 cm. Of these patients, .6 % at 10 years, and 92 % at 15 years. At the time of the analysis, 18 patients (4.4 %) still were alive with detectable local and distant disease, whereas 11 patients (2.7 %) were disease free after treatment. After the exclusion of 16 patients presenting with distant metastases, the study included 80 patients (20.5 %) who experienced at least one recurrence during the study period.
At the time of first recurrence, 61 patients (76.3 %) had only LRR, whereas 13 patients (16.3 %) had only distant recurrence, and 6 patients (7.5 %) had both LRR and distant recurrence. The DFS rate was 87.2 % at 5 years, 80.9 % at 10 years, and 78.8 % at 15 years, whereas the locoregional DFS rate was 89.2 % at 5 years and 83.8 % at 10 years. Therefore, just more than 10 % experienced LRR within 5 years after initial therapy. Table 1 (p \ 0.001), distant metastases (p \ 0.001), incomplete resection (p \ 0.001), and EBRT (p \ 0.001) were significantly associated with a worse CSS. Figure 1a compares the CSS curves between those 45-60 years of age (n = 224) and those older than 60 years (n = 183). As shown in Supplementary Table 3 Figure 1b shows the DFS curves for those 45-60 years of age (n = 222) and those older than 60 years (n = 169). The 16 patients presenting with distant metastases were excluded. Similar to CSS, RAI and EBRT were poor prognostic factors for DFS because patients who received either or both of these treatments generally had more aggressive tumor features and less complete resection. Table 4 presents the multivariate analysis of risk factors for DFS. After adjustment for other significant factors, only tumor size greater than 4 cm (HR 1.733; 95 % CI 1.030-3.058; p = 0.049), central nodal metastases (HR 2.362; 95 % CI 1.010-5.523; p = 0.047), and lateral nodal metastases (HR 4.383; 95 % CI 2.388-8.042; p \ 0.001) were shown to be independent predictors of DFS. When tumor size was entered as a continuous variable, the overall result did not change. Age at diagnosis did not turn out to be an independent predictor of DFS regardless whether it was entered as a categorical or continuous variable.
DISCUSSION
Our data confirmed that advanced age (or age [60 years) is an independent predictor of CSS in older patients with PTC regardless whether it is entered as a continuous or categorical variable. This finding is consistent with what others have reported [4] [5] [6] [7] [8] [9] and supports the argument that perhaps another age cutoff beyond 45 years might be justifiable.
Our data also showed a progressive increase in the risk of cancer-related death as age increased beyond the arbitrary cutoff age of 60 years. This has important implications for current risk stratification systems. 2 After adjustment for other significant prognostic factors, the risk of cancer-related death for those older than 70 years appeared to be significantly higher than for those aged 60-70 years and 45-60 years. In fact, after adjustment for other significant factors, the risk of cancer-related death for patients 60-70 years of age and those older than 70 years relative to those aged 45-60 years was almost 2.5 and 4 times higher, respectively. Based on these findings, it may be argued that perhaps two or more cutoffs after 45 years might be even more appropriate for further improvement of current risk stratification. Although this might be true, we believe having two separate age cutoffs after 45 years increases the complexity of the current stratification system (namely, the TNM staging system) and reduces its practicality and usability. 2 However, interestingly, unlike other recent studies, 11, 12 our data did not show that advanced age significantly increased recurrence when adjustment for other significant factors had been performed. Although those older than 60 years had a significantly lower 10-year DFS than those aged 45-60 years (74.6 vs 84.3 %; p = 0.015), age beyond 60 years did not prove to be an independent predictor for DFS. Therefore, from our analysis, another age cutoff might be appropriate for predicting risk of cancer-related death but less appropriate for predicting disease recurrence in older patients. However, it is worth noting that given the relatively high overall LRR rate and the great proportion of LRR occurring shortly after initial surgery (about 10 % of LRR within 5 years), we strongly suspect that some of these LRRs might have been persistent and residual diseases rather than true recurrences. One possible explanation for this is that because preoperative USG was not routinely performed during the early study period, some of these LRRs might have been nonpalpable nodal metastases that later became clinically evident years after the initial surgery. This also would explain why no preoperative USG was found to be a significant factor of poor DFS and why the rate of DFS significantly improved later in the study period, especially after the year 2001, compared with the earlier periods. Given these confounding factors, it was difficult to interpret the significance of advanced age for DFS. Nevertheless, the factors emphasize the importance of having proper preoperative lymph node mapping by USG, and perhaps, the importance of performing an adequate extent of selective neck dissection, especially in the presence of clinically nodal metastases. Perhaps, this is the precise reason why the dynamic or delayed risk stratification system based on response to therapy might be a better tool for predicting recurrences and DFS than use of the traditional clinicopathologic features. 13, 14 Although the overall impact of nodal metastases on cancer survival still remains a matter of debate, it clearly is significantly greater for older patients. This is supported by several recent studies. 11, 12, 15, 16 Similar to others, our data found that the presence of lateral nodal metastases (or N1b) was an independent predictor of worse CSS and DFS. In fact, the risk of cancer-related death for older patients with N1b was more than five times higher than for older patients without nodal metastases (or N0/Nx). Interestingly, the presence of central nodal metastases (or N1a) also conferred a risk of death more than 2.7 times higher than N0/ Nx, although a significantly higher risk of death was reported recently. 11 However, it is worth noting that because preoperative USG and prophylactic neck dissection were not routinely practiced during most of the study period, these results imply that perhaps only clinically evident or palpable nodal metastases had any significant impact on cancer survival.
Similar to nodal metastases, tumor size also was found to be an independent predictor for CSS and DFS in older patients with PTC. This finding also has been similarly reported by several other groups and concurs with the current 7th-edition UICC TNM staging, which regards both size or local extent (i.e., T staging) and nodal status (N staging) as important components of stage groupings for patients 45 years of age or older. 3 Given the poorer CSS among patients older than 60 years, we advocate a more careful and detailed preoperative staging assessment as well as a more aggressive surgical and therapeutic approach than for their younger counterparts.
Despite these findings, we acknowledge certain shortcomings of our study. First, because the number of patients was moderate, nonsignificant findings in the multivariate analysis might be due to inadequate study power. Second, because this study was conducted over a long period, changes in clinical management were inevitable and might have had a confounding effect on the survival analyses. Also, because the use of pre-and postoperative USG in detecting nodal metastases and prophylactic central neck dissection have become routine in our practice, the current findings represent only our earlier experience. Therefore, larger prospective studies with longer follow-up periods are required to confirm our findings.
CONCLUSION
Advanced age at diagnosis ([60 years) was an independent predictor of CSS in older patients, and the risk of cancerrelated death for those older than 60 years showed a continuing increase. However, advanced age at diagnosis was not an independent predictor of DFS or disease recurrence. Therefore, another age cutoff might be justifiable for stratifying the risk of cancer-related death and less justifiable for stratifying disease recurrence in older patients with PTC. Tumor size as well as central and lateral nodal metastases independently predicted CSS and DFS in older patients.
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